Choosing a therapeutic strategy for patients with high risk of recurrent cardiovascular events | Ukrainian Medical Journal

The article reviews modern approaches to the management of patients with very high and extreme cardiovascular risk. The role of antiplatelet therapy as the basis for secondary prevention of atherothrombotic events is analyzed. Special attention is paid to the problem of gastrointestinal safety and adherence to treatment, as well as the advantages of combined forms of acetylsalicylic acid with an antacid component in the context of preventing «ricochet» thrombosis.

References

1. Navarese E.P., Grzelakowska K., Mangini F. et al. (2022) The spoils of war and the long-term spoiling of health conditions of entire nations. Atherosclerosis, 352: 76–79. doi.org/10.1016/j.atherosclerosis.2022.05.012.
2. Byrne R.A., Rossello X., Coughlan J.J. et al. (2023) 2023 ESC Guidelines for the management of acute coronary syndromes. Eur. Heart J., 44(38): 3720–3826.
3. Starry A., Picker N., Galduf J. et al. (2025) Recurrence of cardiovascular events after an acute myocardial infarction in patients with multivessel disease and associated healthcare costs: A German claims data analysis. Pharmacoeconomics, 43: 177–189.
4. Bhatt D.L., Eikelboom J.W., Connolly S.J. et al. (2020) Role of combination antiplatelet and anticoagulation therapy in diabetes mellitus and cardiovascular disease: Insights from the COMPASS trial. Circulation, 141(23): 1841–1854.
5. Tam F.C., Lin M.Q., Lam T.H. et al. (2025) Atherosclerotic plaque, cardiovascular risk, and lipid-lowering strategies: A narrative review. Front. Cardiovascular. Med., 12: 1659228. doi.org/10.3389/fcvm.2025.1659228.
6. Giubilato S., Lucà F., Abrignani M.G. et al. (2023) Management of residual risk in chronic coronary syndromes. Clinical pathways for a quality-based secondary prevention. J. Clin. Med., 12(18): 5989. doi.org/10.3390/jcm12185989.
7. Khorsandi M., Blumenthal R.S., Blaha M.J. et al. (2024) The ABCs of the 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease. Clin. Cardiol., 47(5): e24284.
8. Pirillo A., Tokgözoğlu L., Catapano A.L. (2024) European lipid guidelines and cardiovascular risk estimation: Current status and future challenges. Curr. Atheroscler. Rep., 26(5): 133–137. doi.org/10.1007/s11883-024-01194-7.
9. Kaufmann C.C., Muthspiel M., Lunzer L. et al. (2024) Antiplatelet therapy and anticoagulation before, during, and after acute coronary syndrome. J. Clin. Med., 13(8): 2313. doi.org/10.3390/jcm13082313.
10. Elbahloul M.A., Mansour A., Galal A. et al. (2026) Clopidogrel versus aspirin monotherapy following dual antiplatelet therapy after percutaneous coronary intervention: An updated meta-analysis of 162,829 patients. Eur. J. Clin. Pharmacol., 82(3): 64. doi.org/10.1007/s00228-025-03942-3.
11. Hammer A., Sinkovec H., Todorovic M. et al. (2024) Adherence to secondary prevention measures after acute myocardial infarction and its impact on patient outcome — A nationwide perspective. J. Clin. Med., 13(16): 4964.
12. Nordenskjöld A.M., Qvarnström M., Wettermark B. et al. (2025) Adherence to secondary preventive treatment following myocardial infarction with and without obstructive coronary artery disease. PLoS One, 20(5): e0324072.
13. Bakker M., Kimenai D.M. (2025) Identifying determinants of cardiovascular medication non-adherence to develop individualised interventions. Heart, 111(14): 649–650. doi.org/10.1136/heartjnl-2024-325638.
14. Rao S.V., O’Donoghue M.L., Ruel M. et al. (2025) 2025 ACC/AHA/ACEP/NAEMSP/SCAI guideline for the management of patients with acute coronary syndromes. Circulation, 151(13): e771–e862. doi.org/10.1161/CIR.0000000000001309.
15. Vrints C., Andreotti F., Koskinas K.C. et al. (2024) 2024 ESC guidelines for the management of chronic coronary syndromes. Eur. Heart J., 45(36): 3415–3537.
16. Dawson J., Béjot Y., Christensen L.M. et al. (2022) European Stroke Organisation guideline on pharmacological interventions for long-term secondary prevention after ischaemic stroke or transient ischaemic attack. European Stroke Journal, 7(3): I–II. doi.org/10.1177/23969873221100032.
17. Hlupeni A., Arooj Y., Adejola A. et al. (2026) Dual antiplatelet therapy use after non-cardioembolic ischemic stroke or transient ischemic attack: A meta-analysis of trials and cohort studies. Front. Neurol., 16: 1750241.
18. Samsky M.D., Mentz R.J., Stebbins A. et al. (2021) Polyvascular disease and increased risk of cardiovascular events in patients with type 2 diabetes: Insights from the EXSCEL trial. Atherosclerosis, 338: 1–6.
19. Bay B., Vogel B., Sharma R. et al. (2025) Inflammatory risk and clinical outcomes according to polyvascular atherosclerotic disease status in patients undergoing PCI. Clin. Res. Cardiol., 114(8): 969–977. doi.org/10.1007/s00392-024-02471-w.
20. Marx N., Federici M., Schütt K. et al. (2023) 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. Eur. Heart J., 44(39): 4043–4140.
21. American Diabetes Association Professional Practice Committee. (2026). Cardiovascular disease and risk management: Standards of care in diabetes — 2026. Diabetes Care, 49(Suppl. 1): S216–S245. doi.org/10.2337/dc26-S010.
22. Cebrian A., Escobar C., Aranda U. et al. (2022) The 2021 European Society of Cardiology cardiovascular disease prevention guidelines: Adding albuminuria to the SCORE scale increases the prevalence of very high/high cardiovascular risk among patients with chronic kidney disease. Clin. Kidney J., 15(6): 1204–1208.
23. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group et al. (2024) KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int., 105(4S): S117–S314.
24. Doomun I., Doomun D., Schukraft S. et al. (2024) Predictive value of HAS-BLED and HEMORR2HAGES bleeding risk scores after percutaneous coronary intervention. Texas Heart Institute J., 51(2): e238267. doi.org/10.14503/THIJ-23-8267.
25. Bhagirath V., Kovalova T., Wang J. et al. (2024) Bleeding risk prediction in patients treated with antithrombotic drugs according to the anatomic site of bleeding, indication for treatment, and time since treatment initiation. TH Open, 8(1): e121–e131. doi.org/10.1055/a-2259-1134.
26. Passacquale G., Sharma P., Perera D. et al. (2022) Antiplatelet therapy in cardiovascular disease: Current status and future directions. Br. J. Clin. Pharmacol., 88(6): 2686–2699. doi.org/10.1111/bcp.15221.
27. Della Bona R., Giubilato S., Palmieri M. et al. (2024) Aspirin in primary prevention: Looking for those who enjoy it. J. Clin. Med., 13(14): 4148.
28. Lanas A., Scheiman J. (2007) Low-dose aspirin and upper gastrointestinal damage: Epidemiology, prevention and treatment. Curr. Med. Res. Opin., 23(1): 163–173.
29. Abrignani M.G., Lombardo A., Braschi A. et al. (2023) Proton pump inhibitors and gastroprotection in patients treated with antithrombotic drugs: A cardiologic point of view. World J. Cardiol., 15(8): 375–394. doi.org/10.4330/wjc.v15.i8.375.
30. Lavie C.J., Howden C.W., Scheiman J. et al. (2017) Upper gastrointestinal toxicity associated with long-term aspirin therapy: Consequences and prevention. Curr.Probl. Cardiol., 42(5): 146–164. doi.org/10.1016/j.cpcardiol.2017.01.006.
31. Zviahina O.V. (2025) Ацетилсаліцилова кислота у профілактиці серцево-судинних захворювань: докази та міфи. Укр. мед. часопис, 6(172): 1–9. doi.org/10.32471/umj.1680-3051.269405.
32. Wang J. (2025) Research progress of aspirin and aluminum magnesium aspirin in antiplatelet therapy of coronary heart disease. Adv. Clin. Med., 15(8): 1575–1580.
33. Clerici B., Cattaneo M. (2023) Pharmacological efficacy and gastrointestinal safety of different aspirin formulations for cardiovascular prevention: A narrative review. J. Cardiovascular Developm. Dis., 10(4): 137. doi.org/10.3390/jcdd10040137.
34. Laudani C., Giacoppo D., Greco A. et al. (2025). Antiplatelet monotherapies for long-term secondary prevention following percutaneous coronary intervention. J. Clin. Med., 14(15): 5536. doi.org/10.3390/jcm14155536.
35. Gwon H.C., Hahn J.Y., Park K.W. et al. (2012) Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents. Circulation, 125: 505–513. doi.org/10.1161/CIRCULATIONAHA.111.059022.
36. Kim B.K., Hong M.K., Shin D.H. et al. (2012) A new strategy for discontinuation of dual antiplatelet therapy: The RESET trial. J. Am. College Cardiol., 60: 1340–1348.
37. Feres F., Costa R.A., Abizaid A. et al. (2013) Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: The OPTIMIZE randomized trial. JAMA, 310: 2510–2522. doi.org/10.1001/jama.2013.282183.
38. Schulz-Schüpke S., Byrne R.A., ten Berg J.M. et al. (2015) ISAR-SAFE: A randomized double-blind placebo-controlled trial of 6 vs 12 months of clopidogrel therapy after drug-eluting stenting. Eur. Heart J., 36: 1252–1263.
39. Gilard M., Barragan P., Noryani A.A.L. et al. (2015) 6-versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: The ITALIC trial. Journal of the American College of Cardiology, 65: 777–786. doi.org/10.1016/j.jacc.2014.11.008.
40. Colombo A., Chieffo A., Frasheri A. et al. (2014) Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: The SECURITY randomized clinical trial. Journal of the Am. College Cardiol., 64: 2086–2097. doi.org/10.1016/j.jacc.2014.09.008.
41. Hong S.J., Kim J.S., Hong S.J. et al. (2021) 1-month dual-antiplatelet therapy followed by aspirin monotherapy after polymer-free drug-coated stent implantation. JACC: Cardiovascular Interventions, 14: 1801–1811.
42. Angiolillo D.J., Galli M., Collet J.P. et al. (2022) Antiplatelet therapy after percutaneous coronary intervention. EuroIntervention, 17(17): e1371–e1396.